PWUP vs. GLUE, RGNX, RVNC, TSHA, CTNM, ALMS, CRVS, PGEN, TNGX, and TRVI
Should you be buying PowerUp Acquisition stock or one of its competitors? The main competitors of PowerUp Acquisition include Monte Rosa Therapeutics (GLUE), REGENXBIO (RGNX), Revance Therapeutics (RVNC), Taysha Gene Therapies (TSHA), Contineum Therapeutics (CTNM), Alumis (ALMS), Corvus Pharmaceuticals (CRVS), Precigen (PGEN), Tango Therapeutics (TNGX), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry.
PowerUp Acquisition vs.
Monte Rosa Therapeutics (NASDAQ:GLUE) and PowerUp Acquisition (NASDAQ:PWUP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.
Monte Rosa Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, PowerUp Acquisition has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500.
Monte Rosa Therapeutics received 14 more outperform votes than PowerUp Acquisition when rated by MarketBeat users.
80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 19.2% of PowerUp Acquisition shares are owned by institutional investors. 6.5% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 48.0% of PowerUp Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Monte Rosa Therapeutics currently has a consensus price target of $14.00, suggesting a potential upside of 147.35%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Monte Rosa Therapeutics is more favorable than PowerUp Acquisition.
PowerUp Acquisition's return on equity of 0.00% beat Monte Rosa Therapeutics' return on equity.
In the previous week, Monte Rosa Therapeutics had 2 more articles in the media than PowerUp Acquisition. MarketBeat recorded 3 mentions for Monte Rosa Therapeutics and 1 mentions for PowerUp Acquisition. Monte Rosa Therapeutics' average media sentiment score of 1.94 beat PowerUp Acquisition's score of 0.00 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.
Summary
Monte Rosa Therapeutics beats PowerUp Acquisition on 8 of the 11 factors compared between the two stocks.
Get PowerUp Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for PWUP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PowerUp Acquisition Competitors List
Related Companies and Tools
This page (NASDAQ:PWUP) was last updated on 1/21/2025 by MarketBeat.com Staff
